Indication

X-linked agammaglobulinemia

X-linked agammaglobulinemia is a rare primary humoral immunodeficiency disorder caused by pathogenic variants in the Bruton tyrosine kinase gene, occurring almost exclusively in male infants and children. Read more about X-linked agammaglobulinemia

45 drugs 17 manufacturers

Advertisement

Drugs that treat it

Common X-linked agammaglobulinemia therapies.

Showing 19–27 of 45 drugs

Filter & compare in the drug finder →Opens the drug finder with X-linked agammaglobulinemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About X-linked agammaglobulinemia.

X-linked agammaglobulinemia is a rare primary humoral immunodeficiency disorder caused by pathogenic variants in the Bruton tyrosine kinase gene, occurring almost exclusively in male infants and children.

Pathophysiologically, the defect halts early B-lymphocyte differentiation in the bone marrow, resulting in a profound absence of circulating mature B cells and severely diminished or undetectable levels of all serum immunoglobulin classes.

Following the clearance of maternally acquired antibodies during early infancy, affected individuals typically present with severe, recurrent bacterial and enteroviral infections—most commonly including otitis media, sinusitis, pneumonia, and gastrointestinal illnesses.

Personalize your experience

Follow X-linked agammaglobulinemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it